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Abstract
The effect of the administration of pertussis toxin as well as modulators of different subtypes of K channels on the
antinociception induced by the H1-antihistamines pyrilamine, diphenhydramine and promethazine was evaluated in the mouse hot
plate test. Pretreatment with pertussis toxin (0.25 mg:mouse i.c.v.) prevented pyrilamine, diphenhydramine and promethazine
antinociception. The KATP channel openers minoxidil and pinacidil potentiated the antinociception produced by the H1-antihis-
tamines whereas the KATP channel blocker gliquidone prevented the anti H1-induced analgesia. The Ca
2-gated K channel
blocker apamin antagonized pyrilamine, diphenhydramine and promethazine analgesia. Pretreatment with an antisense oligonucle-
otide (aODN) to mKv1.1, a voltage-gated K channel, at the dose of 3.0 nmol:single i.c.v. injection, never modified the
antinociception induced by the H1-antihistamines in comparison with degenerate oligonucleotide (dODN)-treated mice. At the
highest effective doses, none of the drugs used modified animals’ gross behaviour nor impaired motor coordination, as revealed
by the rota rod test. The present data demonstrate that both KATP and Ca
2-gated K channels, contrary to voltage-gated K
channel Kv1.1, represent an important step in the transduction mechanism underlying central antinociception induced by
H1-antihistamines. © 1999 Elsevier Science Ltd. All rights reserved.
Keywords: K channel; Antinociception; H1-antihistamines; KATP channel; Ca
2-gated K channel; mKv1.1; Pertussis toxin
www.elsevier.com:locate:neuropharm
1. Introduction
The H1-receptor antagonists are among the most
widely used medications in the world. These com-
pounds produce inhibition of the effects of histamine
mediated by H1 receptors such as smooth-muscle con-
traction in the respiratory and gastrointestinal tracts,
pruritus, sneezing by sensory-nerve stimulation and va-
sodilation (Simons and Simons, 1994). Therefore, their
most common use is as antiallergic drugs. In addition
to these well known peripheral effects, H1-receptor
antagonists produce various central inhibitory actions
(Simons and Simons, 1994). Antihistamines have been
shown to be analgesic adjuvants in both animal and
human studies. They are widely used as adjuvants in
preoperative analgesia as well as in postoperative pain
(Hupert et al., 1980; Sunshine et al., 1989). Clinically,
hydroxyzine decreases the amount of narcotic that is
necessary, provides sedating, and other antihistaminic
effects that are helpful in certain clinical situations.
Furthermore, hydroxyzine itself has some analgesic ef-
fect (Stambaugh and Lane, 1983; Rumore and Schlicht-
ing, 1986). It has also been observed that some other
antihistaminics, such as diphenhydramine, pyrilamine
and promethazine, are endowed with analgesic proper-
ties in both laboratory animals (Rumore and Schlicht-
ing, 1985) and humans (Campos and Solis, 1980;
Rumore and Schlichting, 1986).
Central K channels appear to be involved in the
modulation of pain perception. The central administra-
tion of K channel openers, such as diazoxide, minoxi-
dil, lemakalim and cromakalim, has been reported to
produce antinociception in laboratory animals (Welch
and Dunlow, 1993; Narita et al., 1993) and to potenti-
ate the enhancement of the pain threshold produced by
opioid and a2-adrenoceptor agonists (Vergoni et al.,
1992; Ocan˜a et al., 1996). Furthermore, treatment with
K channel blockers, such as sulphonylureas, 4-
aminopyridine and tetraethylammonium, prevented the
antinociception induced by a2-adrenoceptor, GABAB
and opioid receptor agonists (Ocan˜a and Baeyens,
1993; Raffa and Martinez, 1995).
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Histamine exerts multiple effects on neurones includ-
ing modulation of K currents. The Ca2-activated
K current in rat hippocampal neurones was sup-
pressed by histamine (Haas and Konnerth, 1983). His-
tamine decreased a resting or ‘leak’ K current and
shifted the voltage dependency of a hyperpolarization-
activated current in the lateral geniculate nucleus of the
guinea-pig (Mc Cormick and Williamson, 1991) as well
as reduced K currents in neostriatal interneurones
(Munakata and Akaike, 1994). Furthermore, the in-
volvement of the H1 receptor subtype in the block of
K currents produced by histamine has been reported
(Munakata and Akaike, 1994; Jafri et al., 1997). We,
therefore, thought it worthwhile to investigate the role
of K channels in the antinociception induced by H1-
receptor antagonists. Since several kinds of K chan-
nels with different electrophysiological characteristics
and pharmacological sensitivities have been described
in neurones (Halliwell, 1990; Aronson, 1992), in the
present work we employed different K channel modu-
lators. Apamin has been reported to specifically block
currents through Ca2-activated K channels (Cook,
1988). Sulphonylureas such as gliquidone block KATP
channels in neurones whereas minoxidil and pinacidil
open the same type (KATP) of K channel (Edwards
and Weston, 1993). So far, the blockers of neuronal
voltage-dependent K channels are not selective (Cook
and Quast, 1990; Halliwell, 1990). An antisense
oligonucleotide (aODN) was, therefore, used as a selec-
tive blocker of mKv1.1, a voltage-gated K channel
(Wang et al., 1994). aODNs are short synthetic DNA
segments complementary to sequences of an mRNA
target. By forming DNA:mRNA heteroduplexes,
aODNs can transiently inactivate single genes.
To this purpose we have evaluated the effects pro-
duced by the K channel blockers apamin and gliqui-
done, the K channel openers minoxidil and pinacidil,
as well as an aODN to mKv1.1 in the antinociception
induced by H1-receptor antagonists in the mouse hot-
plate test.
We also investigated whether antinociception induced
by pyrilamine and promethazine, like that produced by
diphenhydramine (Galeotti et al., 1996), was prevented




Male Swiss albino mice (23–30 g) from the Morini
(San Polo d’Enza, Italy) breeding farm were used.
Fifteen mice were housed per cage. The cages were
placed in the experimental room 24 h before the test for
acclimatization. The animals were fed a standard labo-
ratory diet and tap water ad libitum and kept at
2391°C with a 12 h light–dark cycle, light on at 07:00
Fig. 1. Dose-response curve of pyrilamine (5–15 mg:kg s.c.), diphenhydramine (10–20 mg:kg s.c.) and promethazine (3–6 mg:kg s.c.) in the mouse
hot-plate test. Vertical lines represent SEM; between 10 and 14 mice were tested. * PB0.05, ** PB0.01 in comparison with saline-treated mice.
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Fig. 2. Prevention by pertussis toxin (PTX) pretreatment of antinoci-
ception induced by pyrilamine (15 mg:kg s.c.), diphenhydramine (20
mg:kg s.c.) and promethazine (6 mg:kg s.c.) in the mouse hot-plate
test. The test was performed 7 days after a single i.c.v. injection of
vehicle or PTX (0.25 mg:mouse i.c.v.). Vertical lines represent SEM;
between 14 and 18 mice were tested. * PB0.05, ** PB0.01 in
comparison with corresponding analgesic-treated mice.
2.3. Hot-plate test
The method adopted was described by O’Callaghan
and Holtzman (1975). Mice were placed inside a stain-
less steel container, which was set thermostatically at
52.590.1°C in a precision water-bath from KW Me-
chanical Workshop, Siena, Italy. Reaction times (s),
were measured with a stopwatch before and 15, 30, 45
and 60 min after pyrilamine, diphenhydramine and
promethazine. The endpoint used was the licking of the
fore or hind paws. Those mice scoring less than 12 and
more than 18 s in the pretest were rejected (30%). An
arbitrary cut-off time of 45 s was adopted.
The licking latency values reported in all figures were
evaluated in relation to the maximum analgesic effect
of pyrilamine, diphenhydramine and promethazine
which was reached 15 min after administration.
2.4. Rota-rod test
The test was performed according to the method
described by Kuribara et al. (1977). Briefly, the appara-
tus consisted of a base platform and a rotating rod of 3
cm diameter with a non-slippery surface. The rod was
placed at a height of 15 cm from the base. The rod, 30
cm in length, was divided into five equal sections by six
disks. Thus, up to five mice were tested simultaneously
on the apparatus, with a rod-rotating speed of 16 r.p.m.
The integrity of motor coordination was assessed on
the basis of endurance time of the animals on the
rotating rod. One day before the test, the animals were
trained twice. On the day of the test only the mice that
were able to stay balanced on the rotating rod between
90 and 120 s (cut-off time) were selected for testing. The
performance time was measured before and 15, 30, 45
and 60 min after treatment.
2.5. Antisense oligonucleotides
The 24mer phosphodiester oligonucleotides were
capped by a terminal phosphorothioate double substi-
tution and purified by chromatography (Genosys, The
Woodlands, USA). The antisense ODN (5%-CGA CAT
CAC CGT CAT GAT GAA AGC-3%) was designed to
target the 5% portion of the murine Kv1.1 (mKv1.1)
mRNA, residues 575-598 of the published cDNA se-
quence (Chandy et al., 1990). A fully degenerate 24mer
ODN was used as control.
Mice were randomly assigned to antisense
oligodeoxyribonucleotide (mKv1.1 aODN), degenerate
oligodeoxyribonucleotide (mKv1.1 dODN) or vector
groups. A total of 600 mM ODNs were preincubated at
37°C for 30 min with 13 mM DOTAP (N-[1-(2,3-di-
oleoyloxy)propyl]-N,N,N-trimethylammonium methyl
sulphate), used as the vector. Each group received a
single intracerebroventricular (i.c.v.) injection on days
1, 4 and 7.
h. All experiments were carried out in accordance with
the European Communities Council Directive of 24
November 1986 (86:609:EEC) for experimental animal
care.
2.2. Intracerebro6entricular injection technique
Intracerebroventricular (i.c.v.) administration was
performed under ether anaesthesia, according to the
method described by Haley and McCormick (1957).
Briefly, during anaesthesia, mice were grasped firmly by
the loose skin behind the head. A 0.4 mm external
diameter hypodermic needle attached to a 10 ml syringe
was inserted perpendicularly through the skull and no
more than 2 mm into the brain of the mouse, where 5
ml were then administered. The injection site was 1 mm
to the right or left from the midpoint on a line drawn
through to the anterior base of the ears. Injections were
performed into the right or left ventricle randomly. To
ascertain that the drugs were administered exactly into
the cerebral ventricle, some mice (20%) were injected
with 5 ml of diluted 1:10 India ink and their brains
examined macroscopically after sectioning. The accu-
racy of the injection technique was evaluated and the
percentage of correct injections was 95.
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2.6. Drugs
The following drugs were used: pyrilamine maleate,
promethazine hydrochloride, minoxidil, pinacidil,
apamin, pertussis toxin (RBI); diphenhydramine hy-
drochloride (De Angeli); gliquidone (Boehringer
Ingelheim).
Drugs were dissolved in isotonic (NaCl 0.9%) saline
solution, with the exception of pinacidil, that was dis-
solved in a water and dimethyl sulphoxide (DMSO)
(3:1) vehicle. Drug concentrations were prepared in
such a way that the necessary dose could be adminis-
tered in a vol. of 5 ml:mouse by i.c.v. injection and
10 ml:kg by subcutaneous (s.c.) injection.
Apamin, gliquidone, minoxidil and pinacidil were
injected i.c.v 15 min before the test. The drug admin-
istration schedule was chosen on the basis of prelimi-
nary experiments in which the time-course and the
dose-response curves for every compound were deter-
mined.
Concerning pertussis toxin treatment, mice were
randomly assigned to a vehicle (water solution con-
taining 0.01 M sodium phosphate buffer, pH 7.0,
with 0.05 M sodium chloride) or a pertussis toxin
group (0.25 mg:mouse) which received a single i.c.v.
injection on day 0. The hot-plate test was performed
7 days after pretreatment.
Following the pretreatment schedule with saline, ve-
hicle, aODN or dODN mentioned in the above sec-
tion, the antinociceptive effect of pyrilamine,
diphenhydramine and promethazine was tested 72 h
after the last i.c.v. injection. The administration
schedule of ODNs employed was chosen on the basis
of preliminary experiments in which the dose-response
and time-course curves for aODN to mKv1.1 were
determined (Galeotti et al., 1997a).
2.7. Statistical analysis
All experimental results are given as the mean9
SEM. Analysis of variance (ANOVA), followed by
Fisher’s Protected Least Significant Difference (PLSD)
procedure for post-hoc comparison, was used to ver-
ify significance between two means. Data were
analysed with the StatView software for the Macin-
tosh (1992). PB0.05 were considered significant.
Fig. 3. Prevention by the KATP blocker gliquidone (3.0–6.0 mg:mouse i.c.v.) of pyrilamine (15 mg:kg s.c.), diphenhydramine (20 mg:kg s.c.) and
promethazine (6 mg:kg s.c.) antinociception in the mouse hot-plate test. Vertical lines represent SEM; between 10 and 15 mice were tested.
* PB0.05, ** PB0.01 in comparison with the corresponding analgesic-treated mice.
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Fig. 4. Enhancement of pyrilamine (15 mg:kg s.c.), diphenhydramine (20 mg:kg s.c.) and promethazine (6 mg:kg s.c.) antinociception by the KATP
openers minoxidil (10 mg:mouse i.c.v.) and pinacidil (25 mg:mouse i.c.v.) in the mouse hot plate test. Vertical lines represent SEM; between 14 and
19 mice were tested. * PB0.05 in comparison with corresponding analgesic-treated mice.
Fig. 5. Prevention by the Ca2-gated K channel blocker apamin (0.1–1.0 ng:mouse i.c.v.) of pyrilamine (15 mg:kg s.c.), diphenhydramine (20
mg:kg s.c.) and promethazine (6 mg:kg s.c.) antinociception in the mouse hot-plate test. Vertical lines give SEM; there were 15 mice:group.
* PB0.05, ** PB0.01 in comparison with saline-treated mice.
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3. Results
3.1. Effect of pertussis toxin on H1-antihistamine
antinociception
Pyrilamine (5–15 mg:kg s.c.), diphenhydramine (10–
20 mg:kg s.c.) and promethazine (3–6 mg:kg s.c.) pro-
duced a dose-dependent antinociception in the mouse
hot-plate test (Fig. 1).
Pertussis toxin (PTX), administered at the dose of
0.25 mg:mouse i.c.v. 7 days prior to the test, led to a
prevention of the antinociceptive effect of pyrilamine
(15 mg:kg s.c.), diphenhydramine (20 mg:kg s.c.) and
promethazine (6 mg:kg s.c.) as illustrated in Fig. 2.
3.2. Effect of KATP channels modulators on
H1-antihistamine antinociception
The effect produced by the blocker (gliquidone) and
the openers (minoxidil, pinacidil) of KATP channels on
the enhancement of the pain threshold produced by
pyrilamine (15 mg:kg s.c.), diphenhydramine (20 mg:kg
s.c.) and promethazine (6 mg:kg s.c.) was investigated
in the mouse hot-plate test.
The administration of the KATP channel blocker gli-
Fig. 7. Effect of pyrilamine (15–25 mg:kg s.c.), diphenhydramine
(20–30 mg:kg s.c.) and promethazine (6–10 mg:kg s.c.) in the mouse
rota rod test. Vertical lines give SEM; there were 10 mice:group.
* PB0.05, ** PB0.01 in comparison with saline-treated mice.
Fig. 6. Lack of effect of an antisense ODN (aODN) to the mKv1.1
gene on pyrilamine- (15 mg:kg s.c.), diphenhydramine- (20 mg:kg
s.c.) and promethazine- (6 mg:kg s.c.) induced antinociception in the
mouse hot plate test. Mice were injected with antisense ODN (aODN)
or degenerated ODN (dODN) at the dose of 3.0 nmol:single i.c.v.
injection on days 1, 4 and 7. The test was performed 72 h after the
last i.c.v. injection of degenerate dODN or aODN. Vertical lines give
SEM; there were 15–18 mice:group. ** PB0.01 in comparison with
saline-treated mice.
quidone (5–6 mg:mouse i.c.v.), 15 min before the mouse
hot-plate test, prevented the antinociception induced by
pyrilamine, diphenhydramine and promethazine (Fig.
3). A lower dose of gliquidone (3 mg:mouse i.c.v.) was
ineffective (Fig. 3).
Both KATP channel openers minoxidil (10 mg:mouse
i.c.v.) and pinacidil (25 mg:mouse i.c.v.), injected 15 min
before the test, potentiated the antinociceptive activity
of all the H1-antagonists investigated (Fig. 4).
In the same experimental conditions, neither gliqui-
done (Fig. 3) nor minoxidil and pinacidil (Fig. 4)
modified the licking latency values of mice when given
alone.
3.3. Effect of the Ca2-acti6ated K channel blocker
apamin on H1-antihistamine antinociception
The effect produced by the Ca2-activated K chan-
nel blocker apamin on the enhancement of the pain
threshold induced by pyrilamine (15 mg:kg s.c.),
diphenhydramine (20 mg:kg s.c.) and promethazine (6
mg:kg s.c.) was investigated in the mouse hot-plate test.
Apamin (0.5–1 ng:mouse i.c.v.), injected 15 min
before the test, prevented the antinociception induced
by the three H1-antihistamines investigated as illus-
trated in Fig. 5. A lower dose of apamin (0.1 ng:mouse
i.c.v.) did not produce any effect on pyrilamine, diphen-
hydramine and promethazine antinociception (Fig. 5).
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Furthermore, apamin, when given alone, did not
show any hyperalgesic activity (Fig. 5).
3.4. Effect of an aODN to mK61.1 on H1-antihistamine
antinociception
The effect produced by repeated administration of an
antisense oligonucleotide (aODN) to the mKv1.1 gene
on the antinocieption induced by H1-antihistamines was
evaluated by using the mouse hot-plate test. The exper-
iments were performed 72 h after the end of the aODN
administration. aODN, at the concentration of 3 nmol:
i.c.v. injection, did not modify the antinociception in-
duced by pyrilamine (15 mg:kg s.c.), diphenhydramine
(20:mg kg s.c.) and promethazine (6 mg:kg s.c.) in
comparison with the mice pretreated with the degener-
ate oligonucleotide (dODN) as illustrated in Fig. 6.
The pretreatment with the dODN, used as a refer-
ence oligonucleotide, never modified H1-antihistamine
antinociception in comparison with vector i.c.v.-in-
jected mice (data not shown).
The aODN pretreatment did not modify the pain
threshold in mice, having no hyperalgesic or analgesic
effect (Fig. 6).
3.5. Effect of H1-antihistamines on mouse beha6iour
Pyrilamine, diphenhydramine and promethazine, at
the doses used in the present work, elicited their anti-
nociceptive effect without changing the gross behaviour
of the mice.
The three compounds investigated did not alter the
mice motor coordination as revealed by the rota rod
test (Fig. 7). The rota-rod endurance time of mice
treated with pyrilamine (15 mg:kg s.c.), diphenhy-
dramine (20 mg:kg s.c.) and promethazine (6 mg:kg
s.c.) was not modified in comparison with saline-treated
mice (Fig. 7). On the contrary, pyrilamine, diphenhy-
dramine and promethazine, administered at higher
doses (25, 30 and 10 mg:kg s.c., respectively), produced
a significant impairment of the rota-rod performance
by reducing the endurance time on the rotating rod
(Fig. 7).
Furthermore, pyrilamine (15 mg:kg s.c.), diphenhy-
dramine (20 mg:kg s.c.) and promethazine (6 mg:kg
s.c.) did not modify the spontaneous motility of the
mice as revealed by the Animex apparatus (data not
shown).
4. Discussion
Present results indicate that neuronal K channels
play an important role in the mechanism of analgesic
action of the H1-receptor antagonists.
The administration of gliquidone, a potent blocker of
ATP-dependent K channels (KATP) (Amoroso et al.,
1990), prevented the antinociception produced by all
the H1-antagonists investigated. Pretreatment with mi-
noxidil and pinacidil, openers of neuronal KATP chan-
nels (Longman and Hamilton, 1992), potentiated the
enhancement of the pain threshold produced by pyril-
amine, diphenhydramine and promethazine. The func-
tionality of KATP channels appears, therefore,
fundamental in the antinociception induced by block-
ade of the H1 receptors. It has been reported that
stimulation of histamine H1 receptors inhibited KATP
currents (Bonev and Nelson, 1996). On this basis we
can suppose that this potentiation may occur because
minoxidil and pinacidil facilitate the opening of KATP
channels induced by the H1-antagonists.
The intracellular mechanism of the analgesic action
of H1-antihistamines involves the activation of a pertus-
sis toxin (PTX)-sensitive G-protein, since not only
diphenhydramine, as previously reported (Galeotti et
al., 1996), but also pyrilamine and promethazine anal-
gesia is prevented by the i.c.v. administration of PTX.
PTX-sensitive G-proteins represent the most wide-
spread modulatory signaling pathway in neurones
(Holz et al., 1986) and are responsible for modulation
of ionic conductance through a direct interaction with
the ion channel and:or by lowering intracellular cyclic
AMP levels (Hille, 1994). KATP channels can be opened
through a mechanism mediated by G-proteins. It has
been reported that the interaction between the a-GTP
subunit and the KATP channel produces a conforma-
tional change that stimulates the opening of the channel
(Edwards and Weston, 1993). In the presence of
GTPgS, a non hydrolyzable GTP analogue, an irre-
versible activation of KATP is obtained. Furthermore,
the a subunits involved in the modulation of KATP
channel function have been identified as belonging to
the ai and ao subtypes (Edwards and Weston, 1993).
From this evidence it is plausible to suppose that KATP
channels are involved in the analgesia induced by H1-
antagonists as an intracellular effector underlying the
activation of a Gi:o protein.
The present study also provides evidence for the
involvement of Ca2-gated K channels in the anti-
nociception induced by H1-antihistamines. The i.c.v.
administration of the bee venom apamin, a blocker of
small (low) conductance Ca2-gated K channels
(Rudy, 1988), prevented the enhancement of the pain
threshold produced by pyrilamine, diphenhydramine
and promethazine indicating the important role of
Ca2-gated K channels in modulation of the pain
threshold produced by blockade of histamine H1 recep-
tors. These results are supported by electrophysiological
studies in which histamine decreased the post-spike
slow after-hyperpolarization, a long-duration outward
Ca2-dependent K current which hyperpolarizes the
membrane potential (Weinreich, 1986; Weinreich and
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Wonderlin, 1987), in hippocampal pyramidal cells
(Haas and Konnerth, 1983) and in vagal afferent neu-
rones (Jafri et al., 1997).
By using an antisense ODN (aODN) to the mKv1.1
gene coding for the mouse Shaker-like Kv1.1, the in-
volvement of this voltage-gated K channels in central
antinociception induced by H1-antihistamines can also
be excluded. mKv1.1 is a K channel of the Shaker-
like subfamily that, when expressed in Xenopus oocytes,
gives rise to a fast activating, slowly inactivating K
current (Hopkins and Tempel, 1992). The investigation
into the involvement of mKv1.1 in central analgesia
was carried out on the basis of its wide distribution in
the mammalian brain including areas involved in the
modulation of the pain threshold (Wang et al., 1994).
Repeated i.c.v. administration of aODN to mKv1.1 did
not modify pyrilamine, diphenhydramine and
promethazine antinociception. We can exclude the pos-
sibility that the lack of prevention exerted by anti-
mKv1.1 could be due to the employment of inadequate
concentrations since, at the dose used in the present
study, aODN was able to prevent antinociception in-
duced by morphine, baclofen (Galeotti et al., 1997a),
tricyclic antidepressants (Galeotti et al., 1997b) as well
as to modulate different neuronal functions such as
learning and memory (Meiri et al., 1997) and food
consumption (Ghelardini et al., 1997). Furthermore, the
specificity for mKv1.1 channels of the aODN used in
the present investigation has been confirmed by results
obtained from a quantitative RT-PCR which indicated
a lowering of mKv1.1 mRNA brain levels specifically in
the anti-mKv1.1 aODN-treated mice (Galeotti et al.,
1997a,b).
In these experimental conditions, neither the K
channel blockers (gliquidone, apamin), nor the K
channel openers (minoxidil, pinacidil) used modified the
licking latency values of mice in comparison with con-
trol groups. The lack of effect of both gliquidone and
apamin agrees with results of studies in which these
compounds did not modify the nociceptive threshold
against thermal noxious stimuli (Welch and Dunlow,
1993; Raffa and Martinez, 1995; Welch et al., 1995)
excluding that the prevention of pyrilamine, diphenhy-
dramine and promethazine antinociception is due to an
hyperalgesic effect of the K channel blockers used.
The administration of the K channel opener minoxidil
has been reported to induce antinociception in the tail
flick test, but this effect was detectable only at doses
higher than those employed in the present study (Welch
and Dunlow, 1993). We can, therefore, rule out that the
potentiation of H1-antihistamine antinociception could
be subsequent to an enhancement of the pain threshold
produced by minoxidil and pinacidil.
Pyrilamine, diphenhydramine and promethazine ex-
erted their antinociceptive activity altering the motor
coordination of the mice as revealed by the rota-rod
test. Furthermore, the antihistamines did not modify
the spontaneous motility as revealed by the Animex
apparatus (data not shown). The administration of
histamine H1 receptor antagonists produces various
inhibitory effects including sedation (Simons and Si-
mons, 1994) whose appearance could lead to a modifi-
cation of the licking latency values observed in the
hot-plate test. It has been, therefore, necessary to
choose doses of pyrilamine, diphenhydramine and
promethazine at which these compounds showed anti-
nociceptive properties without any behavioural side
effects. Similarly, the K channel modulators and the
aODN to mKv1.1 were used at doses which did not
modify the animals’ behaviour as revealed by the rota
rod and hole board tests (Galeotti et al., 1997a; Ghelar-
dini et al., 1997, 1998).
In conclusion, the present data demonstrate that
both KATP and Ca2-gated K channels are an impor-
tant intracellular effector in the antinociceptive activity
of H1-antihistamines.
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